Staff Profile

Dr Vignes Anand Srinivasalu

Designation: Scientist C

Division/Unit: Clinical Research

Email: vignesanand[dot]s[at]icmr[dot]gov[dot]in

Educational Qualification

MBBS., FDiab., FCC., FInfDis

Personal Statement

Dr. Vignes Anand Srinivasalu is a clinician-scientist with over a decade of clinical experience and more than seven years in research, currently serving as Scientist ‘C’ (Medical) at ICMR–NIRT. His work spans randomized trials, drug and vaccine studies, and epidemiological research in tuberculosis. He provides care for TB patients, including drug-resistant cases, while actively mentoring students and healthcare professionals. He has contributed to Cochrane Diagnostic Test Accuracy Reviews and WHO TB diagnostic guidelines. With numerous peer-reviewed publications, his research focuses on infectious diseases, particularly tuberculosis, aiming to advance diagnostics, treatment, and public health outcomes.

Research Focus

• Clinical trials, particularly randomized controlled trials on novel anti-TB drugs and treatment regimens
• Systematic reviews and meta-analyses covering diagnostic, prognostic, and interventional research
• Biostatistics, data analysis, and AI-assisted approaches in TB diagnosis and management
• Diagnostic and therapeutic research in extrapulmonary TB, including TB–diabetes interactions
• Infectious diseases and therapeutics, supported by formal training in infectious diseases

Ongoing projects as Principal investigator

1. Utility of MPT64 Immunocytochemistry in Diagnosing and Redefining Treatment Outcomes in Peripheral Tuberculous Lymphadenitis (UMPIRE Study)

2. Development of an Auscultatory Sound Bank in Pulmonary Tuberculosis using a Digital Stethoscope

Significant Publications

1. Goodall RL, Meredith SK, Nunn AJ, et al. Evaluation of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): an open-label, multicentre, randomised, non-inferiority trial.

The Lancet. 2022;400(10366):1858-1868. doi:https://doi.org/10.1016/s0140-6736(22)02078-5 (IF-202.731)

2. Haeuser E, Byrne S, Nguyen J, et al. Global, regional, and national trends in routine childhood vaccination coverage from 1980 to 2023 with forecasts to 2030: a systematic analysis for the Global Burden of Disease Study 2023. The Lancet. 2025;406(10500). doi:https://doi.org/10.1016/s0140-6736(25)01037-2 (IF-88.5)

3. Goodall RL, Nunn AJ, Meredith SK, et al. Long-term efficacy and safety of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): extended follow-up of an open-label, multicentre, randomised, non-inferiority trial. The Lancet Respiratory Medicine. Published online October 1, 2024. doi:https://doi.org/10.1016/s2213-2600(24)00186-3 (IF-38.7)

4. Rosu L, Madan JJ, Tomeny EM, et al. Economic Evaluation of shortened, bedaquiline-containing Treatment Regimens for rifampicin-resistant Tuberculosis (STREAM Stage 2): a within-trial Analysis of a Randomised Controlled Trial. The Lancet Global Health. 2023;11(2):e265-e277. doi:https://doi.org/10.1016/S2214-109X(22)00498-3 (IF-34.3)

5. Inbaraj LR, Srinivasalu VA, Sathya Narayanan MK, et al. Diagnostic accuracy of low-complexity, manual nucleic acid amplification tests for the detection of pulmonary and extrapulmonary tuberculosis in adults and adolescents: a systematic review and meta-analysis∗. The Lancet Microbe. Published online September 2025:101169. doi:https://doi.org/10.1016/j.lanmic.2025.101169 (IF-20.4)

6. Leeberk Raja Inbaraj, Jefferson Walter Daniel, Narayanan M, et al. TB-LAMP (loop-mediated Isothermal amplification) for Diagnosing Pulmonary Tuberculosis in Children. The Cochrane Library. 2023;2023(9). doi:https://doi.org/10.1002/14651858.cd015806 (IF-12.008)

7. Inbaraj LR, Sathya Narayanan MK, Daniel J, et al. Low-complexity manual nucleic acid amplification tests for pulmonary tuberculosis in children. Cochrane Database of Systematic Reviews. 2025;2025(6). doi:https://doi.org/10.1002/14651858.cd015806.pub2 (IF-12.008)

8. Kohli M, Inbaraj LR, Salomon A, et al. Low-complexity automated nucleic acid amplification tests for extrapulmonary tuberculosis and rifampicin resistance in adults and adolescents. Cochrane Database of Systematic Reviews. 2025;2025(8). doi:https://doi.org/10.1002/14651858.cd012768.pub4 (IF-12.008)

9. Inbaraj LR, Daniel J, Rajendran P, et al. Truenat MTB Assays for Pulmonary Tuberculosis and Rifampicin Resistance in Adults. Cochrane Database of Systematic Reviews. 2023;2023(1). doi:https://doi.org/10.1002/14651858.cd015543 (IF-11.874)

10. Inbaraj LR, Daniel J, Kumar M, et al. Truenat MTB assays for pulmonary tuberculosis and rifampicin resistance in adults and adolescents. Cochrane library. 2025;2025(3). doi:https://doi.org/10.1002/14651858.cd015543.pub2 (IF-9.4)